UK – NICE to review its decision making processes

Britain’s cost-effectiveness body NICE has said it will review the methods it uses to develop guidance on drugs, medical devices, and diagnostics.

The review will see NICE look at the processes through which its decisions are made. This will include looking at the way data analytics and real-world evidence can be used in the decision making process. Proposals will be presented for public consultation in the summer of 2020.

Sir Andrew Dillon, chief executive of NICE, commented: “This update is part of the regular review and refresh of our methods to ensure that they are robust and up-to-date.

“NICE is undertaking this review at a time of unprecedented change in the healthcare system, where developments such as personalised medicine, digitalisation of health, and use of cell and gene therapy, mean products are becoming ever more challenging to evaluate…